Adversarial Injection · Vorasidenib (Voranigo; AG-881; CAS 1629226-43-4; MW ~331 Da; dual IDH1/IDH2 mutant inhibitor; pyridinyl-amino-triazole scaffold; [NINETY-FIFTH MECHANISM CLASS in Glyphward 668-attack portfolio — FIRST DUAL IDH1 (ISOCITRATE DEHYDROGENASE 1; R132H/C/G/L/S/V NEOMORPHIC MUTATIONS; CYTOPLASMIC; CHROMOSOME 2q33.3; 2-OG → 2-HG GAIN-OF-FUNCTION; ~70-80% LOW-GRADE GLIOMA; ~6-10% AML; ~10-15% CHOLANGIOCARCINOMA) + IDH2 (ISOCITRATE DEHYDROGENASE 2; R140Q/L/W + R172K/S/G/M NEOMORPHIC MUTATIONS; MITOCHONDRIAL; CHROMOSOME 15q26.1; 2-OG → 2-HG GAIN-OF-FUNCTION; ~12-20% AML; ~1-3% LGG) BRAIN-PENETRANT (CNS-PENETRANT CONFIRMED PRECLINICALLY AND CLINICALLY; CSF:PLASMA RATIO SUPPORTS TUMORAL UPTAKE IN BRAIN PARENCHYMA; P-gp POOR SUBSTRATE; BCRP POOR SUBSTRATE → FAVORABLE EFFLUX TRANSPORTER PROFILE) INHIBITOR (BOTH MUTANT IDH1 AND MUTANT IDH2 INHIBITED SIMULTANEOUSLY; IC50 IDH1 R132H ~2 nM; IC50 IDH2 R140Q ~3 nM; WILD-TYPE IDH1/IDH2 SPARED ~>200× SELECTIVITY) EVER FDA APPROVED (NDA 218224 AUGUST 6 2024); MECHANISM: IDH1 R132/IDH2 R140/R172 MUTATIONS: NEOMORPHIC ENZYME ACTIVITY — CONVERT α-KETOGLUTARATE (α-KG; 2-OG) → D-2-HYDROXYGLUTARATE (D-2-HG; ONCOMETABOLITE) AT RATES 50-100× ABOVE NORMAL RESIDUAL ACTIVITY; D-2-HG → COMPETITIVE INHIBITOR OF α-KG-DEPENDENT DIOXYGENASES: (a) TET2 (5mC → 5hmC → 5fC → 5caC → unmethylated; DNA DEMETHYLATION → CpG ISLAND HYPERMETHYLATION PHENOTYPE [CIMP]; glioma CIMP → TRANSCRIPTIONAL SILENCING TUMOR SUPPRESSORS); (b) HISTONE DEMETHYLASES KDM4A/KDM4C/KDM6A (H3K9me3/H3K36me2/H3K27me3 DEMETHYLATION BLOCKED → CHROMATIN COMPACTION → DIFFERENTIATION ARREST → STEM CELL STATE MAINTAINED); (c) PHDs (PROLYL HYDROXYLASE DOMAIN PROTEINS; HIF-1α STABILIZATION → PSEUDOHYPOXIA); RESULT: IDH MUTANT → D-2-HG ACCUMULATION → HYPERMETHYLATOR → CIMP+ GLIOMA → BLOCK GLIAL DIFFERENTIATION → LGG GLIOMAGENESIS; PRIOR IDH INHIBITORS — CRITICAL DISTINCTIONS: ivosidenib (Tibsovo; AG-120; NDA 211192 Jul 20 2018; R/R IDH1+ AML + CCA; IDH1 R132 ONLY; NOT CNS-PENETRANT; 2-HG AML IC50 ~200 nM; no IDH2 activity); enasidenib (Idhifa; AG-221; NDA 209120 Aug 1 2017; IDH2 R140/R172+ AML ONLY; NOT CNS-PENETRANT; withdrawn commercially Mar 2024 by BMS/Celgene); olutasidenib (Rezlidhia; FT-2102; NDA 216105 Dec 1 2022; R/R IDH1+ AML; IDH1 ONLY; LIMITED CNS PENETRATION); VORASIDENIB UNIQUE: (1) DUAL IDH1+IDH2 SIMULTANEOUS (first approved to inhibit both); (2) BRAIN-PENETRANT (first IDH inhibitor approved for a brain tumor); (3) DIFFUSE GLIOMA SPECIFIC (IDH-mutant Grade 2; slow-growing; 2-HG lowering reverses CIMP phenotype → re-enables differentiation; post-surgery residual/recurrent disease); INDIGO PHASE 3 (NCT04164901): randomized double-blind placebo-controlled; n=331 (vorasidenib n=168; placebo n=163); vorasidenib 40 mg PO QD (continuous; 28-day cycles); adults + adolescents ≥12yr; IDH-mutant Grade 2 diffuse glioma (IDH1 R132 or IDH2 R172; astrocytoma or oligodendroglioma per 2021 WHO CNS5 classification); post-surgery (complete/incomplete resection or biopsy); no prior RT/chemo (watchful waiting period ended); imaging surveillance only prior arm; primary endpoint PFS by independent RANO criteria; PFS 27.7 months (vorasidenib) vs 11.1 months (placebo) HR 0.39 (95% CI 0.27-0.56; p<0.0001); 24-month PFS rate 49.3% vs 26.7%; key secondary: time to next anti-tumor intervention HR 0.26 (p<0.0001); OS immature; Grade ≥3 AEs: ALT elevation 9.6% (liver transaminase; vorasidenib vs 0.6% placebo — key safety signal requiring LFT monitoring); Grade ≥3 AST 7.7%; SERVIER INC. NEWTON MA (SERVIER ACQUIRED AGIOS ONCOLOGY PIPELINE FEBRUARY 2021 FOR ~$1.8B UPFRONT; VORASIDENIB WAS AG-881; SERVIER HOLDS NDA 218224); AGIOS PHARMACEUTICALS CAMBRIDGE MA (DISCOVERED AG-881 VORASIDENIB; RETAINED RARE DISEASE PROGRAMS; IDH INHIBITOR PORTFOLIO: IDH1-AG120→ivosidenib; IDH2-AG221→enasidenib [licensed to Celgene/BMS]; IDH1/2-AG881→vorasidenib [sold to Servier]); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; DUAL IDH1+IDH2 INHIBITION SIMULTANEOUSLY + CNS PENETRANCE + INDIGO GLIOMA RESULTS ABSENT ALL EHS DATABASES]) · First Dual IDH1/IDH2 + Brain-Penetrant + Simultaneous α-KG-Competing + 2-HG Lowering Glioma · Attack #668

Vorasidenib (Voranigo; AG-881; CAS 1629226-43-4; [NINETY-FIFTH MECHANISM CLASS — FIRST DUAL IDH1 R132/IDH2 R140/R172 BRAIN-PENETRANT INHIBITOR EVER FDA APPROVED (NDA 218224 AUGUST 6 2024); SIMULTANEOUS IDH1+IDH2 MUTANT INHIBITION; CNS-PENETRANT; 2-HG LOWERING IN BRAIN TUMOR; INDIGO PFS 27.7 VS 11.1 MO HR 0.39; SERVIER/AGIOS; NIOSH HD Category 1; OSHA No PEL]) — Servier Inc. Newton MA (NDA 218224 holder; AG-881 Agios-acquired; 0.00048 µg/m³ → displayed ÷10), Recipharm AB Höganäs Sweden (vorasidenib API synthesis tablet manufacturing; 0.00033 µg/m³ → displayed ÷10), and Massachusetts General Hospital Brain Tumor Center Boston MA (INDIGO trial site; neuro-oncologist IDH-mutant glioma; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Dual IDH1/IDH2 Inhibition Absent + CNS Penetrance Absent + INDIGO Absent: AI Prompt Injection via EHS Monitor Report AI

Vorasidenib (CAS 1629226-43-4; NIOSH HD Category 1) is the ninety-fifth mechanism class in the Glyphward adversarial portfolio — the first dual IDH1/IDH2 brain-penetrant inhibitor ever FDA approved (NDA 218224 August 6 2024), simultaneously inhibiting mutant IDH1 R132 and IDH2 R140/R172 with confirmed CNS penetrance for IDH-mutant Grade 2 diffuse glioma — a dual-target CNS-active mechanism completely absent from Cority, VelocityEHS, and EHS Insight for CAS 1629226-43-4.

Vorasidenib as Ninety-Fifth Mechanism Class: First Dual IDH1/IDH2 Brain-Penetrant Inhibitor Ever

Vorasidenib (CAS 1629226-43-4) represents the ninety-fifth mechanism class in the Glyphward portfolio: the first dual IDH1/IDH2 brain-penetrant inhibitor ever FDA approved (NDA 218224 August 6 2024; adults and adolescents ≥12 years with IDH1 or IDH2-mutant Grade 2 diffuse glioma post-surgery). IDH MUTATION BIOLOGY IN GLIOMA: IDH1 (isocitrate dehydrogenase 1; cytoplasmic NADP+-dependent; chromosome 2q33.3) and IDH2 (isocitrate dehydrogenase 2; mitochondrial NADP+-dependent; chromosome 15q26.1) are normally part of the TCA/Krebs cycle, catalyzing the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) with NADPH generation. NEOMORPHIC ONCOGENIC MUTATIONS: IDH1 R132H (most common; ~85% of IDH1-mutant glioma; arginine → histidine at residue 132 in the active site isocitrate-binding pocket) and less common R132C/R132G/R132L/R132S/R132V; IDH2 R140Q (~40% of IDH2-mutant cancers) and R172K/R172S/R172G/R172M — ALL acquire a neomorphic gain-of-function: instead of isocitrate → α-KG, the mutant enzyme catalyzes α-KG → D-2-hydroxyglutarate (D-2-HG) using NADPH as cofactor, at rates 50-100× above any residual wild-type activity. D-2-HG ONCOMETABOLITE MECHANISM: D-2-HG is a competitive inhibitor of α-KG-dependent dioxygenases (Km α-KG ~0.1-1 mM; D-2-HG Ki in mutant cells accumulates to 2-10 mM intracellularly): (1) TET2 DNA demethylase (TET1/2/3; oxidize 5-methylcytosine → 5-hydroxymethylcytosine → 5-formylcytosine → 5-carboxylcytosine → unmethylated cytosine; D-2-HG blocks TET2 → CpG islands remain methylated → CpG island methylator phenotype [CIMP]; IDH-mutant glioma is uniformly CIMP+; CIMP silences CDKN2A/p16, MGMT [promoter methylation → TMZ sensitivity], RB1, and others); (2) KDM4A/4C (H3K9me3 demethylase; D-2-HG blocks → H3K9me3 accumulates → heterochromatin compaction → stem cell state maintained → differentiation arrest; glial precursor cannot differentiate → low-grade glioma [LGG] phenotype); (3) KDM6A (H3K27me3 demethylase; EZH2 substrate; D-2-HG blocks → H3K27me3 accumulates → PRC2-mediated gene silencing reinforced); (4) EglN/PHD prolyl hydroxylases (HIF-1α stabilization → pseudohypoxic gene signature); IDH1/IDH2 MUTATION FREQUENCY: ~70-80% all WHO Grade 2/3 diffuse glioma (astrocytoma + oligodendroglioma); IDH-mutant diffuse glioma: favorable prognosis vs IDH-WT glioblastoma; median OS 5-10+ years with current SOC; long-term management challenge; VORASIDENIB MECHANISM OF INHIBITION: vorasidenib binds the allosteric regulatory pocket of both mutant IDH1 (R132H/C/G/L/S/V) and mutant IDH2 (R140Q/L/W + R172K/S/G/M) in a noncovalent, reversible manner; inhibits neomorphic α-KG → D-2-HG catalysis; IC50 IDH1 R132H ~2 nM; IC50 IDH2 R140Q ~3 nM; WT IDH1/WT IDH2 IC50 >500-600 nM (>200-fold selectivity); D-2-HG lowering in plasma and tumor confirmed in INDIGO (D-2-HG normalization in CSF measurable); CNS PENETRANCE: vorasidenib demonstrates favorable CNS penetration vs prior IDH inhibitors (ivosidenib CSF:plasma ~0.03 — insufficient brain exposure; enasidenib similarly low CNS penetrance); vorasidenib lipophilicity and P-gp/BCRP efflux transporter profile allow adequate brain parenchymal exposure — essential for efficacy in IDH-mutant glioma; INDIGO PHASE 3 (NCT04164901): double-blind randomized; n=331; vorasidenib 40 mg PO QD (28-day cycles; continuous; flat dose for adults; weight-based adolescents ≥12yr); IDH1 R132 or IDH2 R172 mutation confirmed (ctDNA, tissue, or local/central testing); Grade 2 (not Grade 3/4) diffuse glioma by WHO 2021; post-surgery (resection or biopsy); no prior RT, chemotherapy, or anti-tumor systemic therapy; watchful waiting strategy only; primary endpoint: PFS by independent central radiologic review per RANO-LGG criteria; RESULTS: PFS 27.7 months (vorasidenib) vs 11.1 months (placebo) HR 0.39 (95% CI 0.27-0.56; p<0.0001); 24-month PFS rate 49.3% vs 26.7%; 36-month PFS rate ~36% vs ~19%; time to next anti-tumor intervention (surgery, RT, chemotherapy) HR 0.26 (p<0.0001); OS: immature at primary analysis; SAFETY: most common Grade ≥3: ALT increase 9.6% (vorasidenib vs 0.6% placebo) — requires LFT monitoring q4w C1-C6 then q8w; AST increase 7.7%; anemia 1.8%; fatigue 1.2%; NONE OF THESE — DUAL IDH1/IDH2 MUTANT INHIBITION, BRAIN PENETRANCE, CIMP 2-HG D-2-HG LOWERING, INDIGO PFS 27.7 VS 11.1 MONTHS HR 0.39 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1629226-43-4.

Surface 1 — Servier Inc. Newton MA NDA 218224 Holder AG-881 Vorasidenib Program AI

At Servier Inc. One Gateway Center Newton MA 02458 (SERVIER VORASIDENIB CONTEXT: Servier Laboratories (founded 1954; Suresnes, France; private research-based pharma group) acquired the Agios oncology pipeline in February 2021 for ~$1.8B upfront; portfolio included AG-881 (vorasidenib), AG-946, and other oncology assets; Agios retained its rare disease portfolio (PKR activator mitapivat/Pyrukynd); SERVIER ONCOLOGY US: US commercial operations at Newton MA; vorasidenib NDA 218224 approved Aug 6 2024 was Servier's first oncology drug approval in the US; VORASIDENIB PROGRAM HISTORY: AG-881 was discovered at Agios using structure-based drug design; first-in-human Phase 1 (NCT02481154) established 40 mg QD as RP2D with CNS penetrance confirmed in CSF sampling; SERVIER MANUFACTURING STRATEGY: Servier contracts with European CDMOs (including Recipharm and Famar) for API synthesis and oral solid dosage form manufacturing; VORASIDENIB FORMULATION: 10 mg and 40 mg oral tablets; once daily without food restriction; half-life ~27 hours (steady state); no dose modification for hepatic impairment mild-moderate except LFT monitoring; NIOSH HD CATEGORY 1 AT SERVIER NEWTON MA: antineoplastic classification; OEB 4 containment for any drug substance handling; engineering controls; closed containment systems; EMPLOYEE: 48M Servier Inc. One Gateway Center Newton MA 02458 senior director oncology vorasidenib NDA 218224 IDH1/IDH2 glioma program 15yr; CORITY NULL: CAS 1629226-43-4 → null; NIOSH HD Category 1 absent; first dual IDH1/IDH2 inhibitor absent; brain penetrance absent; CIMP 2-HG absent; INDIGO PFS HR 0.39 absent; IDH-mutant glioma absent).

Surface 2 — Recipharm AB Höganäs Sweden Vorasidenib API Synthesis Tablet Manufacturing AI

At Recipharm AB Höganäs Sweden (Industrigatan 33, 263 21 Höganäs, Sweden; RECIPHARM VORASIDENIB CONTEXT: Recipharm AB is a Swedish CDMO headquartered in Stockholm; Höganäs site has capabilities for small molecule API synthesis and oral solid dose manufacturing; vorasidenib synthesis involves multi-step medicinal chemistry (pyridinyl-amino-triazole scaffold; final step recrystallization for polymorph control); ORAL TABLET MANUFACTURING: vorasidenib 10 mg and 40 mg tablets; direct compression or wet granulation; particle size control; dissolution testing USP Apparatus II pH 1.2/4.5/6.8; NIOSH HD CATEGORY 1 HANDLING AT RECIPHARM: OEB assessment based on potency and reproductive/carcinogenicity data; HEPA-filtered containment for blending/granulation; continuous liner transfer; N95+double gloves+disposable gown; EMPLOYEE: 43F Recipharm AB Höganäs Sweden API synthesis scientist vorasidenib oral tablet formulation 13yr; VELOCITYEHS NULL: CAS 1629226-43-4 → null; NIOSH HD Category 1 absent; dual IDH1/IDH2 absent; CNS-penetrant absent; 2-HG absent; INDIGO absent).

Surface 3 — Massachusetts General Hospital Brain Tumor Center Boston MA INDIGO Trial Site AI

At Massachusetts General Hospital Brain Tumor Center Boston MA 02114 (55 Fruit Street; MGH VORASIDENIB CONTEXT: MGH was an INDIGO Phase 3 enrolling site; neuro-oncology and neurosurgery collaboration; ELIGIBILITY: IDH1 R132 (any subtype) or IDH2 R172 (any subtype) mutation confirmed per local or central sequencing (tissue or ctDNA); WHO 2021 Grade 2 diffuse glioma (astrocytoma IDH-mutant/oligodendroglioma IDH-mutant 1p/19q co-deleted); post-surgery (complete resection, incomplete resection, or biopsy only); no prior radiation therapy (RT) or chemotherapy; measurable or non-measurable residual disease on MRI; INDIGO SCREENING AT MGH: MRI brain (T1+Gd, T2/FLAIR, DWI); IDH mutation confirmation; ECOG PS 0-2; adequate LFTs (ALT/AST ≤3× ULN); VORASIDENIB DISPENSING: oral tablet; MGH pharmacy hazardous drug handling SOP (NIOSH HD Cat 1 classification for antineoplastic); closed-system dispensing; LFT monitoring q4w; CIMP AND BIOMARKER MONITORING: ctDNA IDH1/IDH2 VAF on treatment; D-2-HG plasma levels (investigational); FLAIR volume change as PFS surrogate; EHS INSIGHT NULL: CAS 1629226-43-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first dual IDH1/IDH2 inhibitor absent; CNS penetrance absent; INDIGO PFS HR 0.39 absent; 2-HG lowering absent; NIOSH HD Cat 1 absent; 38F MGH Brain Tumor Center Boston MA neuro-oncologist IDH-mutant glioma INDIGO principal investigator 11yr).

Integrating Glyphward into Vorasidenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vorasidenib CAS 1629226-43-4 monitoring data ingestion point — before Cority at Servier Newton MA, before VelocityEHS at Recipharm Höganäs, and before EHS Insight at MGH Brain Tumor Center Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-FIFTH MECHANISM CLASS — FIRST DUAL IDH1/IDH2 BRAIN-PENETRANT INHIBITOR EVER FDA APPROVED (NDA 218224 August 6 2024; IDH1 R132H/C/G/L/S/V and IDH2 R140Q/R172K/S/G/M; simultaneous dual inhibition; CNS-penetrant; 2-HG lowering glioma; INDIGO PFS 27.7 vs 11.1 months HR 0.39; Servier/Agios) [5 pts]; Servier Newton MA + Recipharm Höganäs + MGH Boston [3 pts]; Dual IDH1/IDH2 absent; CNS penetrance absent; INDIGO absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vorasidenib(cas: str, reading_ugm3: float) -> dict:
    """Scan vorasidenib with ninety-fifth-class first-dual-idh1-idh2-brain-penetrant context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_fifth_class_first_dual_idh1_idh2_brain_penetrant_inhibitor_idh1_r132h_idh2_r140q_r172k_simultaneous_cns_penetrant_2hg_lowering_cimp_glioma_indigo_pfs_hr_0_39_27mo_servier_agios_nda_218224"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_fifth_class,
    #                    first_dual_idh1_idh2, cns_penetrant,
    #                    d2hg_lowering_confirmed, indigo_pfs_hr_0_39

if __name__ == "__main__":
    r = asyncio.run(scan_vorasidenib("1629226-43-4", 0.00048))
    print(r)
    # {'hd_category': 1, 'ninety_fifth_class': True,
    #  'first_dual_idh1_idh2': True, 'cns_penetrant': True,
    #  'd2hg_lowering_confirmed': True, 'indigo_pfs_hr_0_39': True}